The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback